Two Sigma Advisers
VNDA icon

Two Sigma Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

Two Sigma Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,049,300
Closed -$9.25M – 2102
2025
Q4 		$9.25M Buy
1,049,300
+140,000
+15% +$771K 0.02% 572
2025
Q3 		$4.54M Buy
909,300
+100,100
+12% +$463K 0.01% 782
2025
Q2 		$3.82M Buy
809,200
+574,000
+244% +$2.51M 0.01% 838
2025
Q1 		$1.08M Buy
235,200
+78,900
+50% +$368K ﹤0.01% 1444
2024
Q4 		$749K Buy
156,300
+15,700
+11% +$75.4K ﹤0.01% 1600
2024
Q3 		$659K Sell
140,600
-73,500
-34% -$394K ﹤0.01% 1596
2024
Q2 		$1.21M Sell
214,100
-489,800
-70% -$2.53M ﹤0.01% 1456
2024
Q1 		$2.89M Sell
703,900
-182,600
-21% -$731K 0.01% 1033
2023
Q4 		$3.74M Buy
886,500
+118,200
+15% +$477K 0.01% 949
2023
Q3 		$3.32M Buy
768,300
+142,600
+23% +$792K 0.01% 924
2023
Q2 		$4.12M Buy
625,700
+48,300
+8% +$310K 0.01% 855
2023
Q1 		$3.92M Buy
577,400
+124,000
+27% +$872K 0.01% 926
2022
Q4 		$3.35M Buy
453,400
+15,600
+4% +$152K 0.01% 954
2022
Q3 		$4.33M Sell
437,800
-147,900
-25% -$1.56M 0.01% 803
2022
Q2 		$6.38M Sell
585,700
-300
-0.1% -$3.11K 0.02% 662
2022
Q1 		$6.63M Buy
586,000
+38,600
+7% +$507K 0.02% 682
2021
Q4 		$8.59M Buy
547,400
+159,100
+41% +$2.77M 0.02% 554
2021
Q3 		$6.66M Sell
388,300
-20,800
-5% -$364K 0.02% 663
2021
Q2 		$8.8M Buy
409,100
+83,800
+26% +$1.5M 0.02% 620
2021
Q1 		$4.89M Buy
325,300
+55,700
+21% +$902K 0.01% 862
2020
Q4 		$3.54M Sell
269,600
-42,200
-14% -$508K 0.01% 969
2020
Q3 		$3.01M Sell
311,800
-129,800
-29% -$1.39M 0.01% 959
2020
Q2 		$5.05M Buy
441,600
+24,400
+6% +$276K 0.01% 792
2020
Q1 		$4.32M Buy
417,200
+35,100
+9% +$435K 0.02% 763
2019
Q4 		$6.27M Buy
382,100
+4,200
+1% +$63.5K 0.01% 755
2019
Q3 		$5.02M Sell
377,900
-42,200
-10% -$588K 0.01% 759
2019
Q2 		$5.92M Buy
420,100
+118,600
+39% +$1.89M 0.01% 766
2019
Q1 		$5.55M Buy
301,500
+72,800
+32% +$1.66M 0.01% 804
2018
Q4 		$5.98M Sell
228,700
-43,300
-16% -$1.02M 0.02% 743
2018
Q3 		$6.24M Sell
272,000
-28,100
-9% -$574K 0.02% 740
2018
Q2 		$5.72M Buy
300,100
+162,600
+118% +$2.72M 0.02% 801
2018
Q1 		$2.32M Buy
137,500
+30,300
+28% +$507K 0.01% 1178
2017
Q4 		$1.63M Sell
107,200
-44,100
-29% -$654K ﹤0.01% 1334
2017
Q3 		$2.71M Buy
151,300
+4,200
+3% +$70.3K 0.01% 1065
2017
Q2 		$2.4M Buy
147,100
+32,800
+29% +$473K 0.01% 1113
2017
Q1 		$1.6M Sell
114,300
-46,500
-29% -$663K 0.01% 1372
2016
Q4 		$2.56M Buy
160,800
+31,900
+25% +$513K 0.01% 1055
2016
Q3 		$2.15M Buy
128,900
+73,800
+134% +$994K 0.01% 997
2016
Q2 		$617K Buy
+55,100
New +$534K ﹤0.01% 1419

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's VNDA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 1,049,300 shares — an estimated $9.25M sold.

Two Sigma Advisers first reported a position in VNDA in Q2 2016 and held it in 39 quarters. The position peaked at $9.25M in Q4 2025. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,049,300 Vanda Pharmaceuticals shares in Q1 2026, an estimated $9.25M.
  • Two Sigma Advisers first reported a position in Vanda Pharmaceuticals in Q2 2016 and held it in 39 quarters.
  • Two Sigma Advisers's Vanda Pharmaceuticals position peaked at $9.25M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.